Intersect ENT, Inc. (XENT): Price and Financial Metrics

Intersect ENT, Inc. (XENT)

Today's Latest Price: $19.28 USD

0.15 (0.78%)

Updated Dec 1 4:00pm

Add XENT to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

XENT Stock Summary

  • XENT's price/sales ratio is 7.5; that's higher than the P/S ratio of 81.01% of US stocks.
  • With a year-over-year growth in debt of 599.93%, Intersect ENT Inc's debt growth rate surpasses 96.89% of about US stocks.
  • As for revenue growth, note that XENT's revenue has grown -23.68% over the past 12 months; that beats the revenue growth of just 15.01% of US companies in our set.
  • Stocks that are quantitatively similar to XENT, based on their financial statements, market capitalization, and price volatility, are CNTG, RMED, ECOR, QUOT, and REFR.
  • Visit XENT's SEC page to see the company's official filings. To visit the company's web site, go to

XENT Stock Price Chart Interactive Chart >

Price chart for XENT

XENT Price/Volume Stats

Current price $19.28 52-week high $31.46
Prev. close $19.13 52-week low $5.97
Day low $18.60 Volume 166,400
Day high $19.52 Avg. volume 568,670
50-day MA $17.39 Dividend yield N/A
200-day MA $16.01 Market Cap 630.82M

Intersect ENT, Inc. (XENT) Company Bio

Intersect ENT provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. The company was founded in 2003 and is based in Menlo Park, California.

XENT Latest News Stream

Event/Time News Detail
Loading, please wait...

XENT Latest Social Stream

Loading social stream, please wait...

View Full XENT Social Stream

Latest XENT News From Around the Web

Below are the latest news stories about Intersect ENT Inc that investors may wish to consider to help them evaluate XENT as an investment opportunity.

Intersect ENT Announces Agreement to Acquire Fiagon AG Medical Technologies for €60 Million Paid Over Three Years

MENLO PARK, Calif. and BERLIN--(BUSINESS WIRE)--Intersect ENT Announces Agreement to Acquire Fiagon AG Medical Technologies for €60 Million Paid Over Three Years

Business Wire | September 15, 2020

Intersect ENT inks distribution pact with AllianceRx Walgreens Prime for its sinus implant

Intersect ENT ([[XENT]] +4.3%) has executed a pharmacy services agreement with AllianceRx Walgreens Prime for national specialty pharmacy distribution of the Company’s SINUVA (mometasone furoate) Sinus Implant.The agreement will facilitate broader physician and patient access to SINUVA through either a patient’s medical or pharmacy insurance benefit.SINUVA is a non-surgical, corticosteroid-eluting implant...

Seeking Alpha | September 11, 2020

The Daily Biotech Pulse: Positive Readout From Galapagos, Intersect ENT Strikes Distribution Deal, Sol Gel's Regulatory Filing Accepted For Review

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 10) Agenus Inc (NASDAQ: AGEN ) Akouos Inc (NASDAQ: AKUS ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Harmony Biosciences Holdings Inc (NASDAQ: HRMY ) Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Silk Road Medical Inc (NASDAQ: SILK ) Shockwave Medical Inc (NASDAQ: SWAV ) Trillium Therapeutics Inc (NASDAQ: TRIL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 10) ADiTx Therapeutics Inc (NASDAQ: ADTX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC )(reac...

Benzinga | September 11, 2020

Intersect ENT Announces Specialty Pharmacy Partnership Agreement with AllianceRx Walgreens Prime to Distribute SINUVA® Sinus Implant

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Announces Specialty Pharmacy Partnership Agreement with AllianceRx Walgreens Prime to Distribute SINUVA® Sinus Implant

Business Wire | September 10, 2020

Intersect ENT, Inc. (XENT) CEO Thomas West on Q2 2020 Results - Earnings Call Transcript

Intersect ENT, Inc. (XENT) Q2 2020 Results Earnings Conference Call August 04, 2020, 08:30 AM ET Company Participants Richard Meier - Executive VP & CFO Thomas West - President & CEO Conference Call Participants Chris Pasquale - Guggenheim Ravi Misra - Berenberg Suraj Kalia - Oppenheimer & Company. Presentation Operator...

SA Transcripts on Seeking Alpha | August 9, 2020

Read More 'XENT' Stories Here

XENT Price Returns

1-mo 20.80%
3-mo 5.99%
6-mo 51.45%
1-year -8.58%
3-year -35.95%
5-year -6.77%
YTD -22.57%
2019 -11.64%
2018 -13.02%
2017 167.77%
2016 -46.22%
2015 21.29%

Continue Researching XENT

Want to see what other sources are saying about Intersect ENT Inc's financials and stock price? Try the links below:

Intersect ENT Inc (XENT) Stock Price | Nasdaq
Intersect ENT Inc (XENT) Stock Quote, History and News - Yahoo Finance
Intersect ENT Inc (XENT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9135 seconds.